Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
At least 40 subjects in each of the following age groups: 1-\<5 years and 5-\<18 years. No minimum required numbers in the \<1 year age group.
Age
0–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female \<18 years of age (neonates must be at least 36 weeks gestational age).
Diagnosis of pediatric glaucoma or elevated intraocular pressure.
Evidence of a personally signed and dated informed consent document indicating that the subject (and/or a legally acceptable representative) has been informed of all pertinent aspects of the study. A signed and dated assent will be required where applicable according to local laws.
For treated subjects only:
Continuously treated with latanoprost for at least 1 month within the year prior to the baseline examination.
For untreated subjects only:
Continuously treated with latanoprost or other topical prostaglandin analogues for less than one month prior to the baseline examination (based on the best knowledge of treating ophthalmologists), and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period; OR
No prior treatment with latanoprost or other topical prostaglandin analogues, and unlikely to be treated with latanoprost or other topical prostaglandin analogues during the three-year study period.
You may not be if
Unable/unwilling to comply with protocol.
Pregnant or nursing females at baseline.
For treated subjects only: a history of allergy or hypersensitivity to any of the ingredients contained in latanoprost (e.g., hypersensitivity to benzalkonium chloride).
Clareo Health | Long-Term Non-Interventional Latanoprost Study
